ABVC BIOPHARMA, INC.
ABVC Biopharma is an early-stage biotechnology company developing a pipeline of seven drugs and one medical device licensed from related parties. Its candidates focus on central nervous system and oncology or hematology conditions, and include botanical drug products and Vitargus, a vitreous substitute for vitrectomy surgery. ABVC selects technologies from research institutions in the Asia-Pacific region and advances candidates through development and clinical trials with investigators and partners in the United States, Australia and Taiwan. After Phase II trials, it seeks partners to complete later-stage studies and commercialize products, subject to regulatory approval. ABVC makes money through outlicensing intellectual property and providing contract development and manufacturing organization services. Through BioKey, it operates a certified GMP manufacturing facility that supplies small quantities of drugs for clinical trials and provides manufacturing services. BioKey also makes maitake mushroom dietary supplements in tablet and liquid forms. ABVC is headquartered in Fremont, California.
No SEC Form 4 filings for $ABVC in the last 30 days.
See all $ABVC insider activity →ABVC BioPharma raised $3.39 million through discounted convertible notes, with proceeds for working capital, subsidiary funding, and a $625,000 settlement with Lind Global Fund II. The settlement resolves a financing dispute and related lawsuit, including warrant shares and a 12-month financing right for Lind.
ABVC BIOPHARMA, INC. (ABVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million November 2, 2026 (GLOBE NEWSWIRE) - ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), today
ABVC BIOPHARMA, INC. (ABVC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement On August 21, 2026, ABVC BioPharma, Inc. (the “ Company ”) completed the previously announced partial legal and structural separation (the “ Reorganization Transactions ”) of its subsidiary, BioKey (Cayman), Inc., an exempted c
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ABVC (ABVC BIOPHARMA, INC.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.
Recent ABVC coverage spans financial news, corporate actions and mergers & acquisitions.
Dilutive convertible financing and a litigation settlement payment increase near-term funding pressure and potential dilution risk.
The financing adds near-term liquidity but is dilutive risk via convertible note conversion at a discount to recent VWAP.
The distribution creates a new publicly‑reporting entity (BioKey Cayman) and leaves ABVC with a controlling 85% stake, potentially affecting ABVC's balance sheet and shareholder value.
The article offers a comprehensive overview of ABVC BioPharma, including current stock status, financial metrics, and company focus, which can inform trading decisions.
Recent updates indicate positive developments in ABVC BioPharma Inc.'s pipeline, financials, and strategic partnerships, suggesting potential bullish momentum.
AlphAI scores every news story that mentions ABVC with an AI model for sentiment and relevance, and aggregates insider trades from ABVC BIOPHARMA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ABVC BioPharma raised $3.39 million through discounted convertible notes, with proceeds for working capital, subsidiary funding, and a $625,000 settlement with Lind Global Fund II. The settlement resolves a financing dispute and related lawsuit, including warrant shares and a 12-month financing right for Lind.
4 min readABVC BIOPHARMA, INC. (ABVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million November 2, 2026 (GLOBE NEWSWIRE) - ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), today
4 min readABVC BIOPHARMA, INC. (ABVC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement On August 21, 2026, ABVC BioPharma, Inc. (the “ Company ”) completed the previously announced partial legal and structural separation (the “ Reorganization Transactions ”) of its subsidiary, BioKey (Cayman), Inc., an exempted c
2 min readThis article provides a detailed overview of ABVC BioPharma, Inc. (NASDAQ: ABVC) stock, including its current price, historical performance, key financial metrics, and upcoming earnings dates. It also describes the company's biopharmaceutical focus and product pipeline, along with essential technical indicators and frequently asked questions for investors.
5 min readThis page provides the latest news and market updates for ABVC BioPharma Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company. It covers news regarding their pipeline advancements in oncology/hematology, CNS disorders, and ophthalmology, including clinical trial progress, regulatory approvals, and global licensing agreements. Recent updates highlight financial results, licensing payments, and strategic partnerships that are shaping the company's growth and market position.
4 min readABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology
2 min read
